Search the Newsreel

General Fusion Group Ltd. Cl A (NASDAQ: GFUZ) Stock Price, News & Analysis

This page provides an overview of General Fusion Group Ltd. Cl A (NASDAQ: GFUZ) stock, including its current price, basic financial fundamentals, and a chart from TradingView. It also offers access to various Kalkine research reports and tools. The article highlights the stock's performance …

Usio (USIO) Fiscal Q2 2026 Earnings Call: Revenue Up 19%, Guidance Raised

Usio (USIO) reported a strong Fiscal Q2 2026, with revenue increasing 19% year over year and adjusted EBITDA more than doubling to $1.1 million, marking its second consecutive profitable quarter. The company raised its full-year 2026 revenue growth guidance to 14%-16% and anticipates continued …

Fusion Micro Finance Share Price Today, Fusion Micro Finance Stock Price Live NSE/BSE Updates

Fusion Fuel Green (HTOO) raises $1.53M in Reg D equity and warrant deal

Fusion Fuel Green PLC announced a private offering under Regulation D, Rule 506(b), successfully raising $1,525,000 USD through the sale of equity securities, including Class A ordinary shares, Pre-Funded Warrants, and Common Warrants. The company indicated that all offered securities have been sold, with …

Biomea Fusion doses first patient in icovamenib-semaglutide study

Biomea Fusion, Inc. (NASDAQ:BMEA) has dosed the first patient in a new arm of its OPAL platform study, evaluating the combination of icovamenib and low-dose semaglutide. This randomized double-blind study aims to assess whether adding icovamenib can enhance weight loss and improve physical function, …

Usio (NASDAQ:USIO) Stock Price Expected to Rise, LADENBURG THALM/SH SH Analyst Says

LADENBURG THALM/SH SH has increased its price target for Usio (NASDAQ:USIO) from $6.25 to $6.75, maintaining a "Buy" rating and implying a significant upside of approximately 151%. This follows Usio's recent quarterly earnings that largely met analyst expectations with $0.01 EPS and $23.68 million …

Biomea Fusion doses first patient in icovamenib-semaglutide study By Investing.com

Biomea Fusion has announced the dosing of the first patient in a new arm of its OPAL platform research study. This study will evaluate icovamenib in combination with low-dose semaglutide against semaglutide alone for individuals who are overweight or obese but do not have …

Biomea Fusion Trial Tests Obesity Drug Combo Beyond Weight Loss

Biomea Fusion has dosed the first patient in a new arm of its OPAL study, evaluating icovamenib in combination with low-dose semaglutide for overweight or obese adults without type 2 diabetes. The study, in collaboration with the University of Leicester, aims to assess whether …

Biomea Fusion Announces First Patient Dosed in OPAL Study

Biomea Fusion has announced the dosing of the first patient in a new arm of its OPAL study, evaluating icovamenib in combination with low-dose semaglutide for overweight or obese individuals without type 2 diabetes. The study aims to assess whether adding icovamenib can enhance …

Usio earnings beat by $0.02, revenue topped estimates

Usio (NASDAQ: USIO) reported its second-quarter earnings, beating analyst EPS estimates by $0.02 with an EPS of $0.010, compared to an expected $-0.010. The company also surpassed revenue estimates, bringing in $23.68M against a consensus of $23.67M. Usio's stock has shown strong performance, rising …

Diffusion Engineers hosts virtual investor meet on Aug 19

Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Biomea Fusion Inc (BMEA), detailing analyst ratings and price targets. Seven analysts have given BMEA a "Buy" rating with a target price of $6.50, representing a significant upside. The report also includes past and projected EPS figures …

USIO: Q2 revenue up 19% year-over-year; guidance raised to 14%-16% growth for 2026

USIO announced a 19% year-over-year revenue growth in Q2, with significant increases across its Card, ACH, and Output Solutions. The company's adjusted EBITDA more than doubled, and it has raised its 2026 revenue growth guidance to 14%-16%, attributing this to new product introductions and …

Earnings call transcript: Usio tops Q2 2026 profit view, lifts revenue outlook

Usio (USIO) exceeded Q2 2026 profit expectations and slightly beat revenue forecasts, reporting earnings of $0.01 per share against an estimated loss of $0.01, and revenue of $23.68 million. The company raised its full-year revenue growth outlook to 14%-16% and saw its shares jump …

Usio Inc (USIO) Q2 Earnings and Revenues Top Estimates

Usio Inc (USIO) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This …

Usio (NASDAQ:USIO) Announces Earnings Results

Usio (NASDAQ: USIO) returns to profit as Q2 2026 revenue hits $23.7M

Usio (NASDAQ: USIO) reported a return to profitability in Q2 2026, with net income of $280,080 compared to a net loss in the prior year, as revenue grew 19% to $23.7 million. This growth was driven by strong performance in ACH, credit card processing, …

Kabra Extrusiontechnik shareholders approve FY26 financials, reappoint directors

Usio Announces Second Quarter 2026 Financial Results

Usio, Inc. announced strong financial results for the second quarter of 2026, with revenue up 19% and Adjusted EBITDA up 128%. The company reported net income of $0.01 per share, a significant improvement from a net loss in the prior year. Usio also raised …

Fusion Fuel Announces BrightHy Solutions Achieved Key Execution Milestones on Two Green Hydrogen Projects in Southern Europe

Fusion Fuel Green PLC announced that its subsidiary, Bright Hydrogen Solutions Limited, achieved key execution milestones on two green hydrogen projects in southern Europe. This includes completing the Front-End Engineering Design (FEED) for a 15 MW industrial green hydrogen production facility and finishing Factory …

Fusion Fuel (HTOO) unit hits key milestones on 15 MW green hydrogen projects

Fusion Micro Finance vs Arohan Financial: Which MFI Stock

Renaissance Technologies LLC Grows Position in Biomea Fusion, Inc. $BMEA

Renaissance Technologies LLC significantly increased its stake in Biomea Fusion, Inc. (NASDAQ:BMEA) by 174.3% in the first quarter, now holding 1.31 million shares, representing 1.82% of the company. Institutional ownership of Biomea Fusion remains very high at 96.72%, with several other hedge funds also …

Kabra Extrusiontechnik publishes EGM notice for preferential issue approval

INTRUSION ($INTZ) Releases Q2 2026 Earnings

INTRUSION ($INTZ) reported its Q2 2026 earnings, missing both revenue and earnings per share estimates. The company reported an EPS of -$0.13 against an estimated -$0.10, and revenue of $1,450,000 versus an estimated $1,861,500. Following the announcement, the stock price decreased by 13.22%.

Intrusion Inc. (INTZ) Reports Q2 Loss, Misses Revenue Estimates

Intrusion Inc. (INTZ) reported a Q2 loss of $0.13 per share, missing the Zacks Consensus Estimate of a $0.1 loss. The company also missed revenue estimates, posting $1.45 million against an expected $3.13 million. Intrusion's stock has underperformed the market this year, and it …

Earnings call transcript: Intrusion swings lower after Q2 2026 miss

Intrusion Inc. (INTZ) reported a wider-than-expected loss of $0.13 per share and missed revenue forecasts with $1.5 million in Q2 2026, leading to an 18.94% stock drop in after-hours trading. Despite a 64% sequential revenue increase driven by a new Texas contract and the …

Is Intrusion Inc (INTZ) Significantly Overvalued After Q2 Earnings Miss?

Intrusion Inc (INTZ) reported its Q2 2026 earnings, showing sequential revenue growth but an annual decline due to contract delays. The company completed the VigilAigent acquisition, which is expected to add $3.5 million in recurring annual revenue. Despite the growth, GuruFocus considers INTZ significantly …

Intrusion Inc. posts Q2 loss but grows revenue 64%, expands AI cybersecurity with VigilAigent buy

Intrusion Inc. reported a Q2 2026 loss of -$0.13 EPS, missing analyst expectations, but saw a 64% sequential revenue growth to $1.45 million. The company is expanding its AI cybersecurity offerings by acquiring VigilAigent, which is expected to add $3.5 million in annual recurring …

Intrusion earnings missed by $0.04, revenue fell short of estimates

INTRUSION INC 2026: Revenue $1.45M, EPS ($0.13) — 10-Q Summary

INTRUSION INC (INTZ) reported its Q2 2026 financial results with revenue of $1.45M and a diluted loss per share of ($0.13), a decline compared to the prior year. The company experienced a net loss of ($2.59M), attributed to delayed federal contract funding and a …

Fusion Fuel Green (HTOO) updates August 2026 PIPE and restructures legal fee obligations

Fusion Fuel Green PLC has updated the terms of its August 2026 private placement (PIPE), restating the number of Class A ordinary shares and warrants to be issued for approximately $1,525,000 in gross proceeds. The company also restructured its legal fee obligations with Bevilacqua …

Intrusion Inc. (INTZ) warns on going concern as losses mount and debt rises

Intrusion Inc. reported a significant deepening of its Q2 2026 net loss, with revenue declining by 22% for the quarter and 36% year-to-date compared to 2025. The company's cash and cash equivalents dwindled to $0.2 million, leading management to express substantial doubt about its …